nach oben

Supportive Care in Cancer

Erschienen in:

01.11.2006 | Original Article

Assessing cognitive function in cancer patients

verfasst von: Janette Vardy, Karen Wong, Qi-long Yi, Alison Park, Paul Maruff, Lynne Wagner, Ian F. Tannock

Erschienen in: Supportive Care in Cancer | Ausgabe 11/2006

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

Some patients with cancer suffer cognitive impairment after chemotherapy. A brief, sensitive instrument is required to screen patients for cognitive impairment. In this study, we compare three possible screening instruments.

Materials and methods

Cancer patients (n=31) who had received adjuvant chemotherapy within 2 years underwent cognitive evaluation on three occasions. Fluent English speakers (n=20) completed the High Sensitivity Cognitive Screen (HSCS), the computer-based Headminder and CogHealth, and the Functional Assessment of Cancer Therapy-cognitive function (FACT-COG) questionnaire. Patients not fluent in English (NESB) (n=11) performed CogHealth and Headminder.

Results

The patients were aged 31–65 years, and 94% were women with breast cancer. At baseline, 6 of 20 (30%) had moderate–severe cognitive impairment on HSCS, 17 of 31 (55%) had scores greater than one standard deviation (SD) below the mean for normative data in one to two of three domains on Headminder, and on CogHealth, 8 of 31 (26%) were greater than one SD below the mean in at least two of six domains. A large practice effect was seen for the HSCS, with moderate–severe cognitive impairment decreasing from 30 to 5% between the first and second assessment. On FACT-COG, 9 of 19 patients (47%) rated their cognition as greater than one SD below that of a pre-chemotherapy breast cancer control group, with impact on quality of life greater than one SD below for 10 of 19 (53%) patients. No correlation was seen between objective cognitive testing and the FACT-COG.

Conclusions

CogHealth and Headminder were suitable for NESB patients. The HSCS is not recommended for longitudinal studies with short intervals between testing due to practice effect. There is poor correlation between the patients’ perception of their cognitive impairment and the objective tests.

van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuy, ME, Rodenhuis S (1998) Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210–218CrossRefPubMed

Wieneke MH, Dienst DE (1995) Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 4:61–66

Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF (1999) Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640–650CrossRefPubMed

Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695–2701PubMed

Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, Silberfarb PM (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493CrossRefPubMed

Tchen N, Juffs HG, Downie FP, Yi QL, Hu H, Chemerynsky I, Clemons M, Crump M, Goss PE, Warr D, Tweedale ME, Tannock IF (2003) Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21:4175–4183CrossRefPubMed

Phillips KA, Bernhard J (2003) Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. J Natl Cancer Inst 95:190–197PubMedCrossRef

Tannock IF, Ahles TA, Ganz PA, van Dam FS (2004) Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 22:2233–2239CrossRefPubMed

Bornstein R (1994) Methodological and conceptual issues in the study of cognitive change in HIV infection. In: Grant I, Martin A (eds) Neuropsychology of HIV Infection. Oxford Univ. Press, New York, pp 146–160

10.

Butters N, Grant I, Haxby J, Judd LL, Martin A, McClelland J, Pequegnat W, Schacter D, Stover E (1990) Assessment of AIDS-related cognitive changes: recommendations of the NIMH workshop on neuropsychological assessment approaches. J Clin Exp Neuropsychol 12:963–978PubMed

11.

White DA, Heaton RK, Monsch AU (1995) Neuropsychological studies of asymptomatic human immunodeficiency virus-type-1 infected individuals. The HNRC group. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1:304–315PubMedCrossRef

12.

Faust D, Fogel BS (1989) The development and initial validation of a sensitive bedside cognitive screening test. J Nerv Ment Dis 177:25–31CrossRefPubMed

13.

Fogel BS (1991) The high sensitivity cognitive screen. Int Psychogeriatr 3:273–288CrossRefPubMed

14.

Collie A, Darby D, Maruff P (2001) Computerised cognitive assessment of athletes with sports related head injury. Br J Sports Med 35:297–302CrossRefPubMed

15.

Collie A, Maruff P, Darby DG, McStephen M (2003) The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test–retest intervals. J Int Neuropsychol Soc 9:419–428CrossRefPubMed

16.

Makdissi M, Collie A, Maruff P, Darby DG, Bush A, McCrory P, Bennell K (2001) Computerised cognitive assessment of concussed Australian rules footballers. Br J Sports Med 35:354–360CrossRefPubMed

17.

Erlanger DM, Kaushik T, Broshek D, Freeman J, Feldman D, Festa J (2002) Development and validation of a web-based screening tool for monitoring cognitive status. J Head Trauma Rehabil 17:458–476PubMed

18.

Erlanger D, Feldman D, Kutner K, Kaushik T, Kroger H, Festa J, Barth J, Freeman J, Broshek D (2003) Development and validation of a web-based neuropsychological test protocol for sports-related return-to-play decision-making. Arch Clin Neuropsychol 18:293–316CrossRefPubMed

19.

Silbert BS, Maruff P, Evered LA, Scott DA, Kalpokas M, Martin KJ, Lewis MS, Myles PS (2004) Detection of cognitive decline after coronary surgery: a comparison of computerized and conventional tests. Br J Anaesth 92:814–820CrossRefPubMed

20.

Miller EN, Wilkie FL (1994) Computerized testing to assess cognition in HIV-positive individuals. In: Grant I, Martin A (eds) Neuropsychology of HIV infection. Oxford Univ. Press, New York, pp 161–175

21.

Gonzalez R, Heaton RK, Moore DJ, Letendre S, Ellis RJ, Wolfson T, Marcotte T, Cherner M, Rippeth J, Grant I (2003) Computerized reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments. J Int Neuropsychol Soc 9:64–71CrossRefPubMed

22.

Collie A, Maruff P, Makdissi M, McCrory P, McStephen M, Darby D (2003) CogSport: reliability and correlation with conventional cognitive tests used in postconcussion medical evaluations. Clin J Sport Med 13:28–32CrossRefPubMed

23.

Erlanger D, Kaushik T, Cantu R, Barth JT, Broshek DK, Freeman JR, Webbe FM (2003) Symptom-based assessment of the severity of a concussion. J Neurosurg 98:477–784PubMedCrossRef

24.

Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMed

25.

Wagner LI, SJ, Cella D, Donninger N (2003) Chemotherapy-related cognitive deficits: A qualitative examination of patients and providers. Ann Behav Med 25:S056

26.

Fan H, Houédé-Tchen N, Yi Q-L, Chemerynsky I, Downie FP, Sabate K, Tannock IF (2005) Fatigue, menopausal symptoms and cognitive function in women following adjuvant chemotherapy for breast cancer: one and two year follow-up of a prospective controlled study. J Clin Oncol 23:8025–8032CrossRefPubMed

27.

Falleti MG, Maruff P, Collie A, Darby DG (2006) Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test–retest intervals. J Clin Exp Neuropsychol (in press)

28.

Symes E, Maruff P, Ajani A, Currie J (2000) Issues associated with the identification of cognitive change following coronary artery bypass grafting. Aust N Z J Psychiatry 34:770–784CrossRefPubMed

29.

Borowicz LM, Goldsborough MA, Selnes OA, McKhann GM (1996) Neuropsychologic change after cardiac surgery: a critical review. J Cardiothorac Vasc Anesth 10:105–111CrossRefPubMed

30.

Woods SP, Weinborn M, Lovejoy DW (2003) Are classification accuracy statistics underused in neuropsychological research? J Clin Exp Neuropsychol 25:431–439PubMed

31.

Taylor MJ, Heaton RK (2001) Sensitivity and specificity of WAIS-III/WMS-III demographically corrected factor scores in neuropsychological assessment. J Int Neuropsychol Soc 7:867–874CrossRefPubMed

32.

Benedict RH, Zgaljardic DJ (1998) Practice effects during repeated administrations of memory tests with and without alternate forms. J Clin Exp Neuropsychol 20:339–352PubMedCrossRef

33.

Collie A, Maruff P, Makdissi M, McStephen M, Darby DG, McCrory P (2004) Statistical procedures for determining the extent of cognitive change following concussion. Br J Sports Med 38:273–278CrossRefPubMed

34.

McCaffrey RJ, Cousins JP, Westervelt HJ, Martynowicz M, Remick SC, Szebenyi S, Wagle WA, Bottomley PA, Hardy CJ, Haase RF (1995) Practice effects with the NIMH AIDS abbreviated neuropsychological battery. Arch Clin Neuropsychol 10:241–250CrossRefPubMed

Titel: Assessing cognitive function in cancer patients
verfasst von: Janette Vardy
Karen Wong
Qi-long Yi
Alison Park
Paul Maruff
Lynne Wagner
Ian F. Tannock
Publikationsdatum: 01.11.2006
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 11/2006
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-006-0037-6

Neu im Fachgebiet Onkologie

10.04.2024 | PSA-Screening | Nachrichten

Springer Medizin

Assessing cognitive function in cancer patients

Abstract

Goals of work

Materials and methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Senkt Schlafapnoe das Überleben bei Lungenkrebs?

Update Onkologie

Springer Medizin

Abstract

Goals of work

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2006

Breaking bad news: evaluation study on self-perceived competences and views of medical and nursing students taking part in a collaborative workshop

Implantation of central venous ports with catheter insertion via the right internal jugular vein in oncology patients—single center experience

Validity of the malnutrition screening tool as an effective predictor of nutritional risk in oncology outpatients receiving chemotherapy

Symptom profiles and palliative care in advanced pancreatic cancer—a prospective study

A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results

Gastrostomies in palliative care

Neu im Fachgebiet Onkologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Senkt Schlafapnoe das Überleben bei Lungenkrebs?

Update Onkologie